Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-08-27
Original SEC Filing: Click here

---

Webplus: SVA/20090827/6-K/2_EX-99.1/000.htm SEC Original: sinovacexh99_1.htm
SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS – Results Show Good Safety Profile and Immunogenicity – BEIJING, Aug. 18 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in

---

---

Webplus: SVA/20090827/6-K/1/000.htm SEC Original: sinovac6k081809.htm
FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-08-27CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085